ARTICLE | Clinical News
Once-daily glatiramer acetate regulatory update
April 18, 2016 7:00 AM UTC
Synthon said it received European approval of its generic once-daily glatiramer acetate, a generic version of once-daily Copaxone from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA, Petah Tikva, Israel), to treat relapsing-remitting multiple sclerosis (RRMS). The company said all 29 member states in EMA’s decentralized review process supported the generic’s approval. Copaxone is a selective major histocompatibility complex class II (MHCII) modulator. ...